

**SETSUKO K. CHAMBERS, MD**  
**PUBLICATIONS:**

1. **(Chambers) Kuki S**, Morgan RL, Tucci JR: Myasthenia gravis and premature ovarian failure. *Arch Int Med* 14:1230-1232, 1981.
2. **Chambers SK**, Schwartz PE: Neutropenia and fever in patients undergoing combination chemotherapy for malignant germ cell tumors of the ovary. *Obstet Gynecol* 68:842-846, 1986.
3. **Chambers SK**, Kapp DS, Peschel RE, Lawrence R, Merino M, Kohorn EI, Schwartz PE: Prognostic factors and sites of failure in FIGO Stage 1 grade 3 endometrial carcinoma. *Gynecol Oncol* 27:180-188, 1987.
4. **Chambers SK**, Chambers JT, Kohorn EI, Schwartz PE: Etoposide (VP-16-213) plus cis-diamminedichloroplatinum as salvage therapy in advanced epithelial ovarian cancer: *Gynecol Oncol* 27:233-240, 1987.
5. Schwartz PE, **Chambers SK**, Chambers JT, Gutmann J, Katopodis N, Foemmel, R.: Circulating tumor markers in the monitoring of gynecologic malignancies. *Cancer*, 60:353-361, 1987.
6. Cole LA, Wong Y, Latif M, Elliott M, Chambers JT, **Chambers SK**, Schwartz PE: Urinary human chorionic gonadotropin free  $\beta$  subunit and  $\beta$  fragment: new markers of gynecologic cancers. *Cancer Res* 48(5):1356-1360, 1988.
7. Peschel RE, Dowling S, Nath R, Kacinski B, Fischer JJ, Chambers JT, **Chambers SK**, Kohorn EI, Schwartz PE: An intracavitary vaginal applicator using Americium-241. *Endocur Hyper Oncol* 4:91-96, 1988.
8. **Chambers SK**, Chambers JT, Kohorn EI, Lawrence R, Schwartz PE: Evaluation of the role of second-look surgery in ovarian cancer. *Obstet Gynecol* 72:404-408, 1988.
9. Kacinski BM, Carter D, Mittal K, Kohorn EI, Bloodgood RS, Donahue J, Donofrio L, Edwards R, Schwartz PE, Chambers JT, **Chambers SK**: High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas. *Int J Radiat Oncol Biol Phys*, 15:823-829, 1988.
10. Schwartz PE, **Chambers SK**, Chambers JT, Tilton K, Foemmel R: CA-125 in peritoneal washings and fluid: correlation with plasma CA-125 and peritoneal cytology. *Obstet Gynecol*, 73:339-342, 1989.
11. **Chambers SK**, Flynn SD, DelPrete SA, Chambers JT, Schwartz, PE: Bleomycin, vincristine, mitomycin-C and cisplatinum in gynecologic squamous cell carcinomas: a high incidence of pulmonary toxicity. *Gynecol Oncol* 32:303-309, 1989.

12. Kramer C, Peschel RE, Goldberg N, Kohorn EI, Chambers JT, **Chambers SK**, Schwartz PE: Radiation treatment of FIGO Stage IVA Carcinoma of the Cervix. *Gynecol Oncol* 32:323-326, 1989.
13. Schwartz PE, Chambers JT, Kohorn EI, **Chambers SK**, Weitzman H, Voynick IM, MacLusky N, Naftolin F: Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer: a prospective randomized trial. *Cancer*, 63:1074-1078, 1989.
14. Kacinski BM, Stanley ER, Carter D, Chambers JT, **Chambers SK**, Kohorn EI, Schwartz PE: Circulating levels of CSF -1 (M-CSF) a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasms. *Int J Radiat Oncol Biol Phys* 17:159-164, 1989.
15. Kacinski BM, Carter D, Kohorn EI, Mittal K, Bloodgood R, Donahue J, Kramer C, Fisher D, Edwards R, **Chambers SK**, Chambers JT, Schwartz PE: Oncogene expression in vivo by ovarian adenocarcinomas and mixed mullerian tumors. *Yale J Biol Med* 62:379-392, 1989.
16. **Chambers SK**, Hait WN, Kacinski BM, Keyes SR, Handschumacher RE: Enhancement of anthracycline growth inhibition in parent and multidrug resistant chinese hamster ovary cells by cyclosporin A and its analogues. *Cancer Res* 49:6275-6279, 1989.
17. Kier R and **Chambers SK**. Surgical transposition of the ovaries: imaging findings in 14 patients. *Am J Roentgenology*, 153:1003-1006, 1989.
18. **Chambers SK**, Chopyk RL, Chambers JT, Schwartz PE, Duffy TP: Development of leukemia after Adriamycin/Cis-platinum treatment for ovarian cancer. *Cancer*, 64:2459-2461, 1989.
19. Peschel RE, Healey GA, Smith RJ, Haffty B, Papadopoulos D, Chambers JT, **Chambers SK**, Kohorn EI, and Schwartz PE. High dose rate remote afterloading for endometrial cancer. *Endocur Hyper Oncol* 5:209-214, 1989.
20. Chambers JT, **Chambers SK**, Schwartz PE: Correlation between measured creatinine clearance and calculated creatinine in ovarian cancer patients. *Gynecol Oncol*, 36:66-68, 1990.
21. Kacinski BM, **Chambers SK**, Carter D, Filderman AE, Stanley ER. The macrophage colony stimulating factor CSF-1, an auto- and paracrine tumor cytokine is also a circulating "tumor marker" in patients with ovarian, endometrial and pulmonary neoplasms. In: Powanda et al, eds. *The Physiological and Pathological Effects of Cytokines*, NYC, NY: Wiley-Liss, Inc., p. 393-400, 1990.
22. Kacinski BM, Yee LD, Carter D, Mittal K, Donofrio L, **Chambers SK**, Wang KI, Yang-Feng T, Rohrschneider LR, Rothwell V: Ovarian adenocarcinomas express fms-

- complementary transcripts and *fms* protein *in vivo* and *in vitro* and often co-express CSF-1. *Am J Pathol* 137:135-147, 1990.
23. Chambers JT, **Chambers SK**, Voynick IM, Schwartz PE: Neoadjuvant chemotherapy for stage X ovarian cancer. *Gynecol Oncol* 37:321-331, 1990.
  24. Kacinski BM, **Chambers SK**, Stanley ER, Carter DC, Tseng PC, Scata KA, Chang D H-Y, Swami R, Pirro M, Nguyen J, Ariza A, Rohrschneider LR, Rothwell V: The cytokine CSF-1 (M-CSF), whose receptors are expressed by endometrial carcinomas *in vivo* and *in vitro*, may also be a circulating tumor marker of neoplastic disease activity for endometrial carcinoma patients. *Int J Radiat Oncol Biol Phys* 19:619-626, 1990.
  25. **Chambers SK**, Chambers JT, Holm C, Schwartz PE: Sequelae of lateral ovarian transposition in unirradiated cervical cancer patients. *Gynecol Oncol* 39:155-159, 1990.
  26. **Chambers SK**, Chambers JT, Kier R, Peschel RE: Sequelae of lateral ovarian transposition in irradiated cervical cancer patients. *Int J Radiat Oncol Biol Phys* 20:1305-1308, 1991.
  27. Kacinski BM, Scata KA, Carter D, Yee LD, King BL, **Chambers SK**, Sapi E, Jones MA, Pirro MH, Stanley ER, and Rohrschneider L. FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas *in vivo* and *in vitro*. *Oncogene*, 6:941-952, 1991.
  28. Frank AH, Tseng PC, Haffty BG, Papadopoulos DP, Kacinski BM, Dowling SW, Carcangiu ML, Kohorn EI, Chambers JT, **Chambers SK**, Peschel RE and Schwartz PE. Adjuvant whole-abdominal radiation therapy in uterine papillary serous carcinoma. *Cancer* 68:1516-1519, 1991.
  29. Samuels M, Peschel RE, Papadopoulos D, Dowling S, Haffty B, Nath R, Chambers J, **Chambers S**, Kohorn EI, Schwartz PE, Fischer JJ. A feasibility study using intracavitary Americium-241 for recurrent pelvic malignancies. *Endocur Hyper Oncol* 7:131-137, 1991.
  30. Schwartz PE, **Chambers SK**, Chambers JT, Kohorn EI and McIntosh S: Ovarian germ cell malignancies: The Yale University Experience. *Gynecol Oncol* 45:26-31, 1992.
  31. Kacinski BM, Mayer AR, King BL, Carter D, **Chambers SK**. Neu protein overexpression in benign, borderline and malignant ovarian neoplasms. *Gynecol Oncol* 44:245-253, 1992.
  32. **Chambers SK**, Gilmore-Hebert M, Kacinski BM, and Benz EJ. Changes in NA,K-ATPase gene expression during granulocytic differentiation of HL60 cells. *Blood* 80(6):1559-1564, 1992.
  33. Mayer AR, **Chambers SK**, Graves E, Holm C, Tseng PC and Schwartz PE: Ovarian cancer staging: Does it require a gynecologic oncologist? *Gynecol Oncol* 47:223-227, 1992.

34. Price FV, **Chambers SK**, Chambers JT, Carcangiu ML, Schwartz PE, Kohorn EI, Stanley ER, and Kacinski BM. CSF-1 concentration in primary ascites of ovarian cancer is a significant predictor of survival. *Am J Obstet Gynecol* 168(2):520-527, 1993.
35. **Chambers SK**, Gilmore-Hebert M, Wang Y, Rodov S, Benz EJ, Kacinski BM: Post-transcriptional regulation of CSF-1 and CSF-1 receptor gene expression during inhibition of phorbol-ester induced monocytic differentiation by dexamethasone and cyclosporin A: Potential involvement of a destabilizing protein. *Exp Hematol* 21:1328-1334, 1993.
36. Yang-Feng TL, Li S, Han H, Claus EB, Carcangiu ML, **Chambers SK**, Chambers JT and Schwartz PE. Allelic loss in ovarian cancer. *Int J Cancer* 54:546-551, 1993.
37. Price FV, **Chambers SK**, Carcangiu ML, Kohorn EI, Schwartz PE, and Chambers JT. Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma. *Gynecol Oncol* 51:383-389, 1993.
38. **Chambers SK**, Lamb L, Kohorn EI, Schwartz PE, Chambers JT. Chemotherapy of recurrent/advanced cervical cancer: Results of the Yale University PBM-PFU protocol. *Gynecol Oncol* 53:161-169, 1994.
39. Rosman M, Hayden CL, Thiel RP, Chambers JT, Kohorn EI, **Chambers SK**, Schwartz PE. Prognostic indicators for poor risk epithelial ovarian carcinoma. *Cancer* 74:1323-1328, 1994
40. **Chambers SK**, Wang Y, Gilmore-Hebert M, Kacinski BM. Post-transcriptional regulation of *c-fms* proto-oncogene expression by dexamethasone and of CSF-1 in human breast carcinomas *in vitro*. *Steroids* 59: 514-522, 1994.
41. **Chambers SK** and Kacinski BM. Messenger RNA decay of macrophage colony stimulating factor in human ovarian carcinomas *in vitro*. *J Soc Gynecol Invest* 1(4): 310-316, 1994.
42. Scutt LM, McCarthy SM, Flynn SD, Lange R, Long S, Smith RC, **Chambers SK**, Kohorn EI, Schwartz PE and Chambers JT. Pitfalls in the pre-operative assessment of clinical stage I endometrial carcinoma on MRI. *Radiology* 194:567-672, 1995.
43. Fishman DA, **Chambers SK**, Schwartz PE, Kohorn EI, and Chambers JT. Extramammary Paget's disease of the vulva: The Yale University Experience. *Gynecol Oncol* 56(2): 266-270, 1995.
44. Resnik E, **Chambers SK**, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT. A phase II study of etoposide, cisplatin, and adriamycin (EPA) chemotherapy in mixed mullerian tumors of the uterus. *Gynecol Oncol* 56(3): 370-375, 1995.

45. **Chambers, SK**, Gertz RE, Ivins CM, and Kacinski BM. The significance of urokinase-type plasminogen activator, its inhibitors and its receptor in ascites of patients with epithelial ovarian cancer. *Cancer* 75:1627-1633, 1995.
46. **Chambers, SK**, Wang Y, Gertz RE, and Kacinski BM. Macrophage colony stimulating factor mediates invasion of ovarian cancer cells through urokinase. *Cancer Res* 55:1578-1585, 1995.
47. Chambers JT, **Chambers SK**, Kohorn EI, Carcangiu ML, Schwartz PE. Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide. *Gynecol Oncol*, 60: 438-442, 1996
48. Fishman DA, Roberts KB, Chambers JT, Schwartz PE, **Chambers SK**. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrial adenocarcinoma. *Gynecol Oncol*, 61(2): 189-196, 1996.
49. Zreik TG, Chambers JT, **Chambers SK**. Parametrial involvement, regardless of nodal status: a poor prognostic factor for cervical cancer. *Obstet Gynecol*, 87: 741-746, 1996.
50. Cass I, Resnik E, Chambers JT, **Chambers SK**, Carcangiu ML, Kohorn EI, Schwartz PE. Combination chemotherapy with Etoposide, Cisplatin, and Doxorubicin in Mixed Mullerian Tumors of the Adnexa. *Gynecol Oncol* 61(3): 309-314, 1996.
51. **Chambers SK**, Davis CA, Chambers JT, Schwartz PE, Lorber MI, Handschumacher RE. Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients. *Clin Cancer Res* 2(10):1699-1704, 1996.
52. **Chambers SK**, Davis CA, Schwartz PE, Kohorn EI, Chambers JT. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: A phase II study. *Clin Cancer Res* 2(10):1693-1698, 1996.
53. Resnik E, **Chambers SK**, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT. Phase II trial of etoposide, cisplatin, and doxorubicin chemotherapy in malignant uterine smooth muscle tumors. *J Surg Oncol* 63:145-147, 1996.
54. **Chambers SK**, Chambers JT, Davis CA, Schwartz PE, Kohorn EI, Lorber MI, Handschumacher RE, Pizzorno G. Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporin A in refractory ovarian cancer patients. *J Clin Oncol* 15:1945-1952, 1997.
55. **Chambers, SK**, Kacinski BM, Ivins, CM, Carcangiu, ML. Overexpression of epithelial CSF-1 and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer; contrasted with a protective effect of stromal CSF-1. *Clin Cancer Res* 3:999-1007, 1997.

56. Bissonnette J, Chambers S, Collins P, Lockwood C, Mendelson C, Myatt L, Polan ML, Shen WH, Szal S. Strengthening research in Departments of Obstetrics and Gynecology. [editorial]. *J Soc Gynecol Invest* 4(3):115-22, 1997.
57. **Chambers SK**, Ivins CM, Carcangiu, ML. Expression of plasminogen activator inhibitor-2 in epithelial ovarian cancer: a favorable prognostic factor, related to the actions of CSF-1. *Int J Cancer* 74:1-5, 1997.
58. Turner BC, Knisely JPS, Kacinski BM, Haffty BG, Gumbs AA, Roberts KB, Frank AH, Peschel RE, Rutherford TJ, Edraki B, Kohorn EI, **Chambers SK**, Schwartz PE, Wilson LD. Effective treatment of pathologic stage I uterine papillary serous carcinoma with vaginal apex radiation therapy and chemotherapy. *Int J Radiat Oncol Biol Phys* 40:77-84, 1998.
59. Price FV, **Chambers SK**, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT. CA125 may not reflect disease status in patients with uterine papillary serous carcinoma. *Cancer* 82:1720-1725, 1998.
60. Chambers JT, Rutherford TJ, Baker L, Kohorn EI, Schwartz PE, Carcangiu ML, **Chambers SK**. Serous carcinoma of the uterus treated with cisplatin, doxorubicin, and etoposide. *Int J Gynecol Cancer* 8:193-196, 1998.
61. **Chambers SK**, Ivins CM, Carcangiu ML. Urokinase-type plasminogen activator in epithelial ovarian cancer: a poor prognostic factor, associated with advanced stage. *Int J Gynecol Cancer* 8:242-250, 1998.
62. **Chambers SK**, Ivins CM, Carcangiu ML. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in epithelial ovarian cancer. *Int J Cancer* 79: 449-454, 1998.
63. Azodi M, **Chambers SK**, Rutherford T, Kohorn EI, Schwartz PE, Chambers JT. Adenocarcinoma in situ of the uterine cervix: the management and outcome. *Gynecol Oncol* 73:348-353, 1999.
64. Toy EP, Chambers JT, Kacinski BM, **Chambers SK**. The activated macrophage colony stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma. *Gynecol Oncol* 80: 194-200, 2001.
65. Cracchiolo BM, Hanauske-Abel HM, Holland B, **Chambers SK**. Procollagen-derived biomarkers in malignant ascites of ovarian cancer: the N-terminal propeptide of procollagen type III (PIIINP) is an independent prognostic indicator for survival. *Gynecol Oncol* 87: 24-33, 2002.
66. Yalcin OT, Rutherford TJ, **Chambers SK**, Chambers JT, Schwartz PE. Vaginal intraepithelial neoplasia: treatment by carbon dioxide laser and risk factors for failure. *Eur J Obstet Gynecol Reprod Biol* 106: 64-68, 2003.

67. Chambers JT, Rutherford TJ, Schwartz PE, Carcangiu ML, **Chambers SK**, Baker L. A pilot study of topotecan treatment of serous carcinoma of the uterus. *Int J Gynecol Cancer* 13:216-222, 2003.
68. **Chambers SK**, Ivins CM, Kacinski BM, Hochberg RB. An unexpected effect of glucocorticoids on stimulation of c-fms proto-oncogene expression in choriocarcinoma cells expressing little glucocorticoid receptor. *Am J Obstet Gynecol* 190:974-85, 2004.
69. Zheng W, Liang S, Yu H, Rutherford TJ, **Chambers SK**, Schwartz PE. Endometrial glandular dysplasia, a newly defined precursor lesion of uterine papillary serous carcinoma; a morphologic study. *Int J Surg Pathol*, 12(3): 207-23, 2004.
70. Liang S, **Chambers SK**, Cheng L, Zhou Y, Zheng W. Endometrial glandular dysplasia, a newly defined precursor lesion of uterine papillary serous carcinoma; a molecular study. *Int J Surg Pathol* 12(4):319-331, 2004.
71. Kelly MG, O'Malley DO, Hui P, McAlpine J, Dzuira J, Rutherford TJ, Azodi M, **Chambers SK**, Schwartz PE. Improved survival in surgical stage 1 patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. *Gynecol Oncol* 95: 469-473, 2004.
72. Tangir J, Bonafe N, Gilmore-Hebert M, **Chambers SK**. SGK-1, a potential regulator of c-fms related breast cancer aggressiveness. *Clin Exp Metastasis* 21: 477-483, 2004.
73. Toy EP, Bonafe N, Savlu A, Zeiss C, Zheng W, Flick M, **Chambers SK**. Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis. *Clin Exp Metastasis* 22(1):1-9, 2005.
74. Bonafe N, Gilmore-Hebert M, Folk NL, Azodi M, Zhou Y, **Chambers SK**. Glyceraldehyde-3-phosphate dehydrogenase binds to the AU-rich 3' UTR of CSF-1 mRNA in human ovarian cancer cells: possible role in CSF-1 post-transcriptional regulation and tumor phenotype. *Cancer Res* 65(9): 3762-3771, 2005.
75. **Chambers SK**. Systematic lymphadenectomy in advanced epithelial ovarian cancer: two decades of uncertainty resolved. *J Natl Cancer Inst*, 97(8):548-549, 2005.
76. **Chambers SK**, Alberts DS, Hatch KD. Response to letters re: Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes in optimally debulked advanced ovarian cancer: a randomized clinical trial. *J Natl Cancer Inst* 97 (21):1622-1623, 2005.
77. Fadare O, Liang SX, Ulukus EC, **Chambers SK**, Zheng W. Putative Precursors of endometrial clear cell carcinoma. *Am J Surg Pathol* 30(12):1519-1530, 2006.

78. Zheng W, Liang SX, Yi X, Ulukus EC, Davis JR, **Chambers SK**. Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma. *Int J Gynecol Pathol* 26(1):38-52, 2007.
79. Zheng W and **Chambers SK**. Letter to the editor re: Histopathology of endometrial hyperplasia and endometrial carcinoma: an update. *Ann Diagn Pathol* 12(3): 231-232, 2008.
80. Zhou Y, Yi X, Stoffer JB, Bonafe N, Gilmore-Hebert M, McAlpine J, **Chambers SK**. The multifunctional protein glyceraldehyde-3-phosphate dehydrogenase is both regulated and controls CSF-1 mRNA stability in ovarian cancer. *Mol Cancer Res* 6(8): 1375-84, 2008. PMID 2587019
81. Yi X, Zhou Y, Zheng W, **Chambers SK**. HuR expression in the nucleus correlates with high histologic grade and poor disease-free survival in ovarian cancer. *Aust NZ J Obstet Gynaecol* 49(1): 93-98, 2009. PMID 19281587
82. Toy EP, Azodi M, Folk NL, Zito CM, Zeiss CJ, **Chambers SK**. Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colony stimulating factor (CSF-1). *Neoplasia* 11(2): 136-144, 2009. PMID 2631138
83. Woo HH, Zhou Y, Yi X, David CL, Zheng W, Gilmore-Hebert, M, Kluger HM, Ulukus EC, Baker T, Stoffer JB, **Chambers SK**. Regulation of non AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer. *Oncogene* 28:1176-1186, 2009. epub ahead of print; doi:10.1038/onc.2008.469, 19 January 2009.
84. **Chambers SK**, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MB, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Nagle RB, Wright HM, Cohen JL, Alberts DS. Overexpression of tissue VEGF-A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in women with resistant ovarian cancer. *Clin Cancer Res* 16(21): 5320-8, 2010.
85. Hess LM, **Chambers SK**, Hatch K, Hallum A, Janicek M, Buscema J, Borst M, Calley C, Slayton L, Chongpison Y, Alberts DS. Pilot study of prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer. *J Support Oncol* 8: 252-258, 2010.
86. Liang SX, Pearl M, Liang S, Xiang L, Jia L, Yang B, Fadare O, Schwartz PE, **Chambers SK**, Kong B, Zheng W. Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger. *Int J Cancer* 128:763-770, 2011. Published on line ahead of print 15 April 2010; DOI: 10.1002/ijc.25395.
87. Toy EP, Lamb T, Azodi M, Roy WJ, Woo HH and **Chambers SK**. Inhibition of the c-fms proto-oncogene autocrine loop and tumor phenotype in glucocorticoid stimulated human breast carcinoma cells. *Breast Cancer Res Treat*: 129(2):411-9, 2011. Published on line ahead of print 10 November 2010; DOI 10.1007/s10549-010-1247-7.



88. Woo HH, Yi X, Lamb T, Menzl I, Baker T, Shapiro DJ, **Chambers SK**. Post-transcriptional suppression of proto-oncogene c-fms expression by vigilin in breast cancer. *Mol Cell Biol* 31(1):215-25, 2011. Published on line ahead of print 25 October 2010: 2010 Oct 25. DOI 10.1128/MCB.01031-10.
89. McCaffrey R, Bahtiyar M, Kohorn EI, Chambers JT, Schwartz PE, **Chambers SK**. Neoadjuvant and Adjuvant Chemotherapy of Cervical Cancer: Mature Results of the Phase II PBM-PFU Protocol. *Int J Gynecol Cancer* 21(3); 535-544, 2011.
90. Jia L, Yi XF, Zhang ZB, Zhuang ZP, Li J, **Chambers SK**, Kong BH, Zheng W. Prohibitin as a novel target protein of luteinizing hormone in ovarian epithelial carcinogenesis. *Neoplasma* 58(2); 104-109, 2011.
91. Li J, Abushahin N, Pang S, Xiang L, **Chambers SK**, Fadare O, Kong B, Zheng W. Tubal origin of "ovarian" low-grade serous carcinoma. *Modern Pathol*, 24:1488-1499, 2011. Published on line ahead of print 24 June 2011: doi:10.1038/modpathol.2011.106.
92. Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, **Chambers SK**, Ghatage P, Pippitt CH, Brown JV, Covens A, Nagarkar RV, Davy M, Leath CA, Nguyen H, Stepan DE, Weinreich DM, Tassoudji M, Sun Y-N, Vergote IB. A randomized, double-blind, placebo-controlled phase 2 study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian carcinoma. *J Clin Oncol* 30:362-371, 2012; Epub ahead of print December 19, 2011 as 10.1200/JCO.2010.34.3178.
93. **Chambers SK**, Chow SH, Janicek MF, Cragun JM, Hatch KD, Cui H, Laughren C, Clouser MC, Cohen JL, Wright HM, Abu Shahin N, Alberts DS. Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer. *Clin Cancer Res* Epub ahead of print March 15, 2012, doi:10.1158/1078-0432.CCR-12-0261. Highlighted in May 1, 2012 *Clin Cancer Res*.
94. Baker A, Roe D, Laughren C, Cohen JL, Wright HM, Cui H, Alberts DS, **Chambers SK**. Investigation of Bendamustine HCL in a phase 2 study in women with resistant ovarian cancer. *Invest New Drugs*, 2012 . (Epub ahead of print 2012 May 13). <http://www.springerlink.com/content/uj57ng3154u46k61/>
95. Woo HH, Laszlo CF, Greco S, **Chambers SK**. Regulation of colony stimulating factor-1 expression and ovarian cancer cell behavior in vitro by miR-128 and miR-152. In press, *Molecular Cancer*, 11:58, 2012.

REVIEWS, CHAPTERS, BOOKS:

1. Kacinski BM and **Chambers SK**. Molecular biology of ovarian cancer. *Curr Opin Oncol* 3:889-900, 1991.
2. Schwartz PE, **Chambers SK**, Chambers JT, Kohorn EI, McIntosh S: The evolution of chemotherapy for ovarian germ cell malignancies. *Transactions of the American Gynecologic and Obstetric Society, AGOS, Mosby Yearbook, Inc. St. Louis MO*, 9:93-100, 1991.
3. Chambers JT and **Chambers SK**. Endometrial Sampling When? Where? Why? With What? *Clin Obstet Gynecol* 35(1):28-39, 1992.
4. **Chambers SK** and Chambers JT. *Gynecologic Neoplasms*. J Noble (ed), Primary Care and General Medicine, Second edition, Mosby-Year Book, Inc. St. Louis, MO, pgs. 1872-1882, 1996.
5. **Chambers SK**, contributor, Expert consultations in gynecologic malignancies. M Markman and JL Belinson (eds), Marcel Dekker, Inc., New York, NY, pgs. 133-134 (case 16), pgs. 175-176 (case 22), pgs. 342-344 (case 43), 1997.
6. **Chambers SK**. *Molecular Biology of Gynecologic Cancers*. VT DeVita, S Hellman, SA Rosenberg (eds), *Cancer: Principles and Practice of Oncology*, Fifth edition, JB Lippincott Company, Philadelphia, PA, pgs. 1427-1432, 1997.
7. **Chambers SK**. *Gynecologic Oncology Model: Research*. CO Granai (ed), *Surgical Oncology Clinics of North America*, WB Saunders Co., Philadelphia PA, pgs. 255-262, 1998.
8. **Chambers SK**. In vitro invasion assays. John Bartlett (ed), *Methods in Molecular Medicine: Ovarian Cancer*, Humana Press, Inc., Totowa, NJ, pgs. 179-185, 2000.
9. Chambers JT and **Chambers SK**. *Gynecologic Neoplasms*. J Noble (ed), Primary Care and General Medicine, Third edition, Mosby-Year Book, Inc. St. Louis, MO, 2000.
10. **Chambers SK**. *Molecular Biology of Gynecologic Cancers*. VT DeVita, S Hellman, SA Rosenberg (eds), *Cancer: Principles and Practice of Oncology*, Sixth edition, JB Lippincott Company, Philadelphia, PA, pgs. 1519-1525, 2001.
11. **Chambers SK**. Invited review: Trends in hormonally-related cancers in US and Japanese women. *Proceedings of the 54<sup>th</sup> Annual Congress of the Japan Society of Obstetrics and Gynecology*, Monduzzi Editore, Bologna, Italy, 2002.
12. **Chambers SK** and Hess LM. Ovarian Cancer Prevention. In Alberts, Hess (Eds), *Fundamentals of Cancer Prevention*, Second Edition, Springer-Verlag: Heidelberg, pgs 447-473, 2008.

13. Garcia FA and **Chambers SK**. Endometrial Cancer Prevention. In Alberts, Hess (Eds), Fundamentals of Cancer Prevention, Second Edition, Springer-Verlag: Heidelberg, pgs 475-494, 2008.
14. Hess LM, **Chambers SK**, Alberts DS. Role of intraperitoneal chemotherapy for ovarian cancer. In: DeVita, Lawrence, and Rosenberg (eds), Principles and Practice of Oncology Updates, Eighth edition, Lippincott, Williams & Wilkins, New York, NY, Vol 22(5): 1-8, 2008.
15. Clouser M, Hess LM, **Chambers SK**. Invited chapter: Biomarker Targets and Novel Therapeutics. In MS Stack, DA Fishman (eds), Ovarian Cancer, Cancer Treat Res 149: 85-105, 2009.
16. **Chambers SK**. Invited review: Role of CSF-1 in progression of ovarian cancer. Future Oncol 5(9): 1429-40, 2009. PMID 2830097
17. Alberts DS and **Chambers SK**. Introduction: Intraperitoneal therapy for ovarian cancer. In Alberts (ed), Intraperitoneal therapy for ovarian cancer, Springer Science+Business Media, 2009.
18. **Chambers SK** and Martinez JD. The significance of p53 isoform expression in serous ovarian cancer. Invited Priority Paper Evaluation, Future Oncol, June 2012.
19. Woo HH and **Chambers SK**. Post-transcriptional regulation of proto-oncogene c-fms in breast cancer. Invited Chapter, In Siregar Y (ed): Oncogene, InTech, August 2012.

#### CASE REPORTS:

1. Cooperberg MR, **Chambers SK**, Rutherford TJ, Foster HE. Cystic pelvic pathology presenting as falsely elevated post void residual urine measured by portable ultrasound bladder scanning: report of the three cases and review of the literature. Urology 55(4):590, 2000.
2. Bloch MH, Hwang WC, Baehring JM, **Chambers SK**. Paraneoplastic limbic encephalitis—ovarian cancer presenting as anterograde amnesia. Obstet Gynecol, 104 (5): 1174-1177, 2004.
3. Klein RL, Brown AR, Gomez-Castro CM, **Chambers SK**, Cragun JM, Grasso-LeBeau L, Lang JE. Ovarian cancer metastatic to the breast presenting as inflammatory breast cancer: a case report and literature review. J Cancer 1:27-31, 2010.